 |
16 Products |  |
56 Diseases | | 16 Products |
|
39 Trials |  |
939 News |  |
| «12...234567891011121314» |
- ||||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial initiation date: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (clinicaltrials.gov) - Aug 8, 2016
P3, N=140, Not yet recruiting, Sponsor: Octapharma
Initiation date: Jun 2016 --> Dec 2017
- | Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial initiation date, Trial primary completion date, HEOR: A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push (clinicaltrials.gov) - Jul 19, 2016
P4, N=30, Recruiting, Sponsor: Octapharma
Initiation date: Jun 2016 --> Dec 2017 Initiation date: Nov 2014 --> Jul 2015 | Trial primary completion date: Dec 2016 --> Dec 2017
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment change, Trial withdrawal, Trial primary completion date: Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=0, Withdrawn, Sponsor: University of California, Los Angeles
Initiation date: Nov 2014 --> Jul 2015 | Trial primary completion date: Dec 2016 --> Dec 2017 N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2016
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial completion, Enrollment change: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=12, Completed, Sponsor: Astellas Institute for Regenerative Medicine
N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2016 Active, not recruiting --> Completed | N=16 --> 12
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial completion, Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=13, Completed, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | N=16 --> 12 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial completion, Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=13, Completed, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial suspension, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Jun 10, 2016
P2, N=60, Suspended, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Suspended
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment closed, Trial primary completion date, Metastases: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=11, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Recruiting --> Suspended Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment closed, Trial primary completion date: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=12, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Enrollment open, Surgery: FORMA-04: Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency (clinicaltrials.gov) - May 6, 2016
P3, N=6, Recruiting, Sponsor: Octapharma
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029 Not yet recruiting --> Recruiting
- Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial primary completion date: Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease (clinicaltrials.gov) - May 5, 2016
P=N/A, N=50, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> Dec 2016
- |||| Nuwiq (simoctocog alfa) / Octapharma
Trial primary completion date: Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - May 4, 2016
P3, N=55, Recruiting, Sponsor: Octapharma
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Balfaxar (prothrombin complex concentrate, human-lans) / Octapharma, Pfizer
New P3 trial, Surgery: Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex (clinicaltrials.gov) - Apr 15, 2016
P3, N=370, Not yet recruiting, Sponsor: Octapharma
- |||||||||| Octagam (intravenous normal human immunoglobulin) / Octapharma
New P3 trial: ProDERM: Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) (clinicaltrials.gov) - Apr 6, 2016
P3, N=94, Not yet recruiting, Sponsor: Octapharma
- Atenativ (human antithrombin III) / Octapharma
Enrollment open, Trial initiation date, Trial primary completion date: Atenativ Effect on Uterine Blood Flow and Preeclampsia (clinicaltrials.gov) - Mar 23, 2016
P4, N=6, Recruiting, Sponsor: Vastra Gotaland Region
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Dec 2015 --> Dec 2017
- | Privigen (human immune globulin intravenous 10%) / CSL Behring, Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion, Octagam (intravenous normal human immunoglobulin) / Octapharma
New P2 trial: Ig PRx in AECOPD: Pilot Study (clinicaltrials.gov) - Feb 24, 2016
P2, N=48, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- | ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment open, Trial primary completion date: Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration (clinicaltrials.gov) - Feb 8, 2016
P1/2, N=12, Recruiting, Sponsor: University of California, Los Angeles
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Dec 2015 --> Dec 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2017
- |||||||||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
New P3 trial: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (clinicaltrials.gov) - Dec 23, 2015
P3, N=140, Not yet recruiting, Sponsor: Octapharma
- Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial primary completion date: Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP (clinicaltrials.gov) - Nov 12, 2015
P2/3, N=2, Terminated, Sponsor: Octapharma
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2017 Trial primary completion date: Apr 2014 --> Oct 2012
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial primary completion date, HEOR: Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps (clinicaltrials.gov) - Oct 23, 2015
P4, N=30, Recruiting, Sponsor: Octapharma
Trial primary completion date: Apr 2014 --> Oct 2012 Trial primary completion date: Jul 2015 --> Dec 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Oct 23, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Aug 2014
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Oct 23, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Trial primary completion date: Aug 2015 --> Aug 2014 Trial primary completion date: Aug 2015 --> Aug 2014
- |||| Nuwiq (simoctocog alfa) / Octapharma
Trial primary completion date: NuProtect: Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII (clinicaltrials.gov) - Oct 22, 2015
P3, N=100, Recruiting, Sponsor: Octapharma
Trial primary completion date: Aug 2015 --> Aug 2014 Trial primary completion date: Apr 2016 --> Apr 2018
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial initiation date, Surgery: FORMA-04: Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency (clinicaltrials.gov) - Oct 22, 2015
P3, N=6, Not yet recruiting, Sponsor: Octapharma
Trial primary completion date: Apr 2016 --> Apr 2018 Initiation date: Aug 2015 --> Dec 2015
- ||| Enrollment open: ATHN 2: Factor Switching Study (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=600, Recruiting, Sponsor: American Thrombosis and Hemostasis Network
Initiation date: Aug 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial completion, Enrollment change: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Oct 16, 2015
P2, N=22, Completed, Sponsor: Octapharma
Not yet recruiting --> Recruiting Recruiting --> Completed | N=18 --> 22
- ||||| ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
New P2 trial, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Sep 30, 2015
P2, N=60, Recruiting, Sponsor: Ocata Therapeutics
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial completion, Enrollment change: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=36, Completed, Sponsor: Rigshospitalet, Denmark
Recruiting --> Completed | N=18 --> 22 Active, not recruiting --> Completed | N=45 --> 36
- ||| New trial: ATHN 2: Factor Switching Study (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=600, Not yet recruiting, Sponsor: American Thrombosis and Hemostasis Network
- | Gammanorm (human immune globulin subcutaneous) / Octapharma
New P4 trial, HEOR: A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push (clinicaltrials.gov) - Jul 20, 2015
P4, N=30, Recruiting, Sponsor: Octapharma
- ||| Octagam (intravenous normal human immunoglobulin) / Octapharma, Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial initiation date: GAM 10-06: Non-Interventional Study on the Tolerability and Efficacy of IVIG (clinicaltrials.gov) - Jun 11, 2015
P4, N=1000, Not yet recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed | N=45 --> 36 Initiation date: Jan 2015 --> Sep 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
New P1/2 trial, Metastases: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) - Jun 4, 2015
P1/2, N=13, Enrolling by invitation, Sponsor: Ocata Therapeutics
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
New P1/2 trial: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) - May 15, 2015
P1/2, N=13, Enrolling by invitation, Sponsor: Ocata Therapeutics
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Enrollment closed, Trial primary completion date: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - May 5, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Initiation date: Jan 2015 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Aug 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment closed, Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Apr 28, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment closed, Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Apr 28, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015
- Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial primary completion date: Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=50, Recruiting, Sponsor: Octapharma
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015 Trial primary completion date: May 2015 --> May 2016
- |||||| Nuwiq (simoctocog alfa) / Octapharma
Enrollment open: Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - Apr 22, 2015
P3, N=55, Recruiting, Sponsor: Octapharma
Trial primary completion date: May 2015 --> May 2016 Not yet recruiting --> Recruiting
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
New P3 trial, Surgery: FORMA-04: Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency (clinicaltrials.gov) - Apr 3, 2015
P3, N=6, Not yet recruiting, Sponsor: Octapharma
- Enrollment closed, Trial primary completion date: RESIST EXP: Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (clinicaltrials.gov) - Apr 1, 2015
P=N/A, N=3, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Completed --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jun 2020
- Trial completion, Enrollment change, Trial primary completion date: RESIST EXP: Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (clinicaltrials.gov) - Mar 5, 2015
P=N/A, N=3, Completed, Sponsor: City of Hope Medical Center
Completed --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jun 2020 Active, not recruiting --> Completed | N=50 --> 3 | Trial primary completion date: Jun 2020 --> Feb 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment closed, Trial primary completion date: Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) (clinicaltrials.gov) - Feb 19, 2015
P1, N=3, Active, not recruiting, Sponsor: CHABiotech CO., Ltd
Active, not recruiting --> Completed | N=50 --> 3 | Trial primary completion date: Jun 2020 --> Feb 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Mar 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment closed, Trial primary completion date: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) (clinicaltrials.gov) - Feb 9, 2015
P1/2, N=16, Active, not recruiting, Sponsor: Ocata Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Oct 2015
- ||||||| Nuwiq (simoctocog alfa) / Octapharma
Trial completion: NuPreviq: Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - Jan 22, 2015
P3, N=66, Completed, Sponsor: Octapharma
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Oct 2015 Active, not recruiting --> Completed
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial primary completion date: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Jan 7, 2015
P2, N=18, Recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Jan 2015
- ||||| Octagam (intravenous normal human immunoglobulin) / Octapharma, Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
New P4 trial: GAM 10-06: Non-Interventional Study on the Tolerability and Efficacy of IVIG (clinicaltrials.gov) - Nov 28, 2014
P4, N=1000, Not yet recruiting, Sponsor: Octapharma
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial primary completion date: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=45, Recruiting, Sponsor: Rigshospitalet, Denmark
Trial primary completion date: Jul 2014 --> Jan 2015 Trial primary completion date: Oct 2014 --> Mar 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology
Trial primary completion date: Oct 2014 --> Mar 2015 Trial primary completion date: Aug 2014 --> Nov 2014
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=16, Recruiting, Sponsor: Advanced Cell Technology
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Aug 2014 --> Nov 2014
- Atenativ (human antithrombin III) / Octapharma
New P4 trial: Atenativ Effect on Uterine Blood Flow and Preeclampsia (clinicaltrials.gov) - Oct 30, 2014
P4, N=6, Not yet recruiting, Sponsor: Vastra Gotaland Region